RayKnowChina Research Map
Shortlist

Cancer

Breast cancer in Hangzhou

杭州 乳腺癌

All diseases in Hangzhou

9 hospitals in Hangzhou

Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Hangzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 110 papers led
  2. 109 papers led
  3. 74 papers led
  4. 64 papers led
  5. 49 papers led
    No open trial led
  6. 49 papers led
  7. 21 papers led
    No open trial led
  8. 6 papers led
    No open trial led
  9. 0 papers led

Breast cancer in every city Hangzhou on the disease page, with the national map

100

open trials on breast cancer with a hospital in Hangzhou

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Hangzhou as lead sponsor or study site. 61 of them are led by a hospital in Hangzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07380646

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07383818

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Xi'an

  3. Recruiting
    RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07413939

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan

  4. Recruiting
    Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07457359

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  5. Recruiting
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07492641

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  6. Recruiting
    Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07498478

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan

  7. Recruiting
    Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07602907

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  8. Recruiting
    Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07616427

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Nanjing

  9. Recruiting
    Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07616440

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  10. Recruiting
    Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07616453

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  11. Recruiting
    Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
    Phase
    Phase 4
    Started
    2026-05
    Posted
    Registry
    NCT07695259

    Age 60 years to Not stated; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  12. Recruiting
    SMP-656 for HER2-Positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07726342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou

  13. Recruiting
    Effects of TDCS Intervention on Neoadjuvant Chemotherapy in Breast Cancer Patients with Mild to Moderate Depression
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06741540

    Age 18 years to 65 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  14. Recruiting
    BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06756932

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

  15. Recruiting
    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06757634

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou

  16. Recruiting
    To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06784921

    Age 18 years to 75 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  17. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06790693

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang

  18. Recruiting
    A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06841354

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  19. Recruiting
    Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06874933

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou

  20. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  21. Recruiting
    A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
    Phase
    Phase 2/Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06926868

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  22. Recruiting
    Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06964906

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  23. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  24. Recruiting
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06977893

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 9 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Urumqi, Xi'an, Zhengzhou

  25. Recruiting
    JS207 Combination Therapy in Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07045311

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou

  26. Recruiting
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07060807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou

  27. Recruiting
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07062965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an

  28. Recruiting
    Dragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07162298

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  29. Recruiting
    An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07222267

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen

  30. Recruiting
    A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07244094

    Age 18 years to 95 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteChangchun, Hangzhou

  31. Recruiting
    A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-10
    Posted
    Registry
    NCT07250386

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  32. Recruiting
    Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07252986

    Age not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  33. Recruiting
    Safety and Feasibility of IRE for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07263451

    Age 18 years to Not stated; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  34. Recruiting
    Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT07284836

    Age 18 years to 70 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  35. Recruiting
    A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07304934

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  36. Recruiting
    A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07330544

    Age 18 years to Not stated; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  37. Recruiting
    Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07340398

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  38. Recruiting
    Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07351487

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Hefei, Shanghai

  39. Recruiting
    A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT07455188

    Age 18 years to Not stated; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  40. Recruiting
    Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
    Phase
    N/A
    Started
    2025-10
    Posted
    Registry
    NCT07469267

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 12 listed hospitals as study sitesChangsha, Guiyang, Hangzhou, Harbin, Jinan, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wuhan

  41. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  42. Recruiting
    Pucotenlimab and Anlotinib in Combination With Chemotherapy
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07896668

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  43. Recruiting
    Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT04744506

    Age 18 years to 85 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  44. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  45. Recruiting
    The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
    Phase
    Phase 3
    Started
    2024-01
    Posted
    Registry
    NCT06214195

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  46. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  47. Recruiting
    A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06371274

    Age 18 years to Not stated; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  48. Recruiting
    The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06452706

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesHangzhou, Harbin, Shanghai, Urumqi, Wuhan, Xi'an

  49. Recruiting
    Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06464913

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  50. Recruiting
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06534762

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  51. Recruiting
    Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06538896

    Age 18 years to 70 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  52. Recruiting
    Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06587789

    Age 18 years to 80 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  53. Recruiting
    Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06596018

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  54. Recruiting
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06611813

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 6 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Urumqi, Zhengzhou

  55. Recruiting
    Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06658080

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou

  56. Recruiting
    Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06671262

    Age 18 years to 85 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  57. Recruiting
    Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06682195

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 10 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Taiyuan, Urumqi, Xi'an, Zhengzhou

  58. Recruiting
    Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06705127

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  59. Recruiting
    Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06832904

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  60. Recruiting
    Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT07899099

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  61. Recruiting
    Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
    Phase
    N/A
    Started
    2023-01
    Posted
    Registry
    NCT04960839

    Age 30 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 5 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  62. Recruiting
    Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT05212454

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  63. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05646862

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan

  64. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  65. Recruiting
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05860465

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan

  66. Recruiting
    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05872347

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou

  67. Recruiting
    A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05894239

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan

  68. Recruiting
    Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT05950945

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Xi'an, Zhengzhou

  69. Recruiting
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-08
    Posted
    Registry
    NCT06043466

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  70. Recruiting
    A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06064812

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  71. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  72. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  73. Recruiting
    Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT06155305

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  74. Recruiting
    Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
    Phase
    Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT06227117

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Tianjin

  75. Recruiting
    Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT07014410

    Age 18 years to 75 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  76. Recruiting
    Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
    Phase
    N/A
    Started
    2023-07
    Posted
    Registry
    NCT07920094

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sir Run Run Shaw Hospital; 10 listed hospitals as study sitesHangzhou, Jinhua, Ningbo, Taizhou, Wenzhou

  77. Recruiting
    A Study for the Neoadjuvant Treatment of Breast Cancer
    Phase
    Phase 4
    Started
    2022-07
    Posted
    Registry
    NCT05420454

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  78. Recruiting
    A Study for the Adjuvant Treatment of Breast Cancer
    Phase
    Phase 4
    Started
    2022-07
    Posted
    Registry
    NCT05420467

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  79. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  80. Recruiting
    Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05731258

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  81. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

  82. Recruiting
    Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
    Phase
    Not given
    Started
    2022-03
    Posted
    Registry
    NCT05856383

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  83. Recruiting
    Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT06551220

    Age 18 years to 80 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai

  84. Recruiting
    Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis
    Phase
    N/A
    Started
    2020-05
    Posted
    Registry
    NCT04158843

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  85. Recruiting
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
    Phase
    Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04557449

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou

  86. Recruiting
    Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2020-09
    Posted
    Registry
    NCT04576143

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  87. Recruiting
    Application of Radiomics in Breast Cancer
    Phase
    Not given
    Started
    2018-01
    Posted
    Registry
    NCT04483804

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  88. Not yet recruiting
    Areola Preservation in NSM With Nipple Involvement
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07544134

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  89. Not yet recruiting
    Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07689929

    Age not stated; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  90. Not yet recruiting
    Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07745257

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 8 listed hospitals as study sitesAnyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou

  91. Not yet recruiting
    SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07787338

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  92. Not yet recruiting
    Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07848984

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  93. Not yet recruiting
    Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07892508

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  94. Not yet recruiting
    Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07188116

    Age 18 years to 80 years; women only (registered criteria)

    Led by Zhejiang Hospital; 1 listed hospital as study siteHangzhou

  95. Not yet recruiting
    Comparing the Safety and Cosmetic Outcomes Between Laparoscopic Versus Traditional Open Breast-conserving Surgery
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06671249

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  96. Not yet recruiting
    Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
    Phase
    Phase 4
    Started
    2023-07
    Posted
    Registry
    NCT05841849

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  97. Not yet recruiting
    Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
    Phase
    Phase 4
    Started
    2023-10
    Posted
    Registry
    NCT05860907

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 6 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Shijiazhuang, Yangzhou, Zhengzhou

  98. Not yet recruiting
    The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
    Phase
    Phase 1/Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06140576

    Age 18 years to 70 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  99. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

  100. Enrolling by invitation
    T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06481956

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Hangzhou

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Hangzhou, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Hospital of Hangzhou Normal University杭州师范大学附属医院nonenonenonenonenonenonenonenonenonenonenone0nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone2none4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone
Children's Hospital, Zhejiang University School of Medicine浙江大学医学院附属儿童医院nonenonenonenonenonenonenone81 open1nonenone5none7nonenone52841 opennone0none1nonenonenone11 opennonenone23313 open4nonenonenonenonenone1221 opennone0none074 opennone0nonenonenone04nonenonenone41nonenone
Chun'an First People's Hospital淳安县第一人民医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第一医院(浙江省中医院)nonenonenone2950none49nonenonenonenone21nonenone2none241 opennone8none24none1nonenonenone4nonenonenone2none33 open1nonenone1none1none1nonenone2none2nonenonenone0nonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital, Chinese Medical University浙江中医药大学附属第一医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院5112588 open6514 open1272 open11514 open6412 open32none1none891 open51 open0556 open513 open11 open146711 opennone411none3201 opennone41 open22117none4104none5none2none020201 open1144none1nonenone0nonenonenonenone
Fourth Affiliated Hospital of Zhejiang University浙江大学医学院附属第四医院nonenone6none93 opennonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenone4nonenonenone
Fourth Affiliated Hospital, Zhejiang Universitynonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou Cancer Hospital杭州市肿瘤医院14nonenone131 open11 opennonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou Children's Hospital杭州市儿童医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou First People's Hospital杭州市第一人民医院8none671151231 open218none1none31nonenone5nonenonenone7nonenonenonenonenonenonenonenonenonenonenone161nonenonenonenone1none2none1none11none0nonenonenone1nonenonenonenonenonenone0nonenonenone
Hangzhou Fuyang District First People's Hospital杭州市富阳区第一人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou Hospital, Zhejiang Chinese Medicine Universitynonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou Lin'an Traditional Chinese Medicine Hospital杭州市临安区中医院nonenonenonenonenonenonenonenonenonenonenone1nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou Linping District First People's Hospital杭州市临平区第一人民医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou Red Cross Hospital杭州市红十字会医院nonenonenonenonenonenonenonenonenonenonenonenone11nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou TCM Hospital, Zhejiang Chinese Medical University杭州市中医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone114nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou Third People's Hospital杭州市第三人民医院nonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou Women's Hospital杭州市妇科医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hangzhou Xixi Hospital杭州市西溪医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone51nonenonenonenonenonenonenonenonenone
Jianggan District People's Hospital杭州市江干区人民医院nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第二医院(浙江省新华医院)nonenonenonenonenonenonenonenonenonenonenone13none1nonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone11nonenonenonenonenonenonenonenonenone
Second Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院143 open689 open596 open11512 open665 open10931 open419 opennone101653052 opennonenone24320 opennonenonenone1none7none41282 opennone368 open9540none4none6none001012nonenone0nonenone11none140nonenonenone
Shaoxing People's Hospital绍兴市人民医院nonenonenone14297none9nonenonenone2none1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenone1nonenone2nonenonenonenonenonenonenonenonenonenonenonenonenone
Shulan Hangzhou Hospital树兰(杭州)医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone
Sir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院41833 open44831 open29491 open15nonenonenone102nonenone4nonenonenone7nonenonenone1nonenone30nonenonenone232 open11nonenone1none010nonenone0none1none3none0none10nonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第三医院(浙江省中山医院)nonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tongde Hospital浙江省立同德医院0nonenone20nonenonenonenonenonenonenone08nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Women's Hospital浙江大学医学院附属妇产科医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone6nonenonenonenonenonenone0nonenonenone0nonenonenonenonenonenonenonenone1nonenonenonenone1nonenonenone
Xiaoshan Traditional Chinese Medical Hospital杭州市萧山区中医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Zhejiang Cancer Hospital浙江省肿瘤医院196 open506 open353 open10611 open2047 open232 open11015 open180nonenone200none2none22137 opennonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenone1none1nonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone
Zhejiang Hospital浙江医院nonenonenonenone31none6nonenonenonenone02nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone90none1nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Zhejiang Hospital浙江医院nonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone02 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Zhejiang Provincial People's Hospital浙江省人民医院4411938691 open533 open741 open241 opennone0none401010nonenonenone151 opennonenonenonenonenonenonenone2nonenonenone1253nonenonenone1none1none1none00none4nonenonenone42nonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Hangzhou.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for breast cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Hangzhou on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data